×
For best experience we recommend to activate Javascript in your browser.
Recombinant RAGE antibody
The Human Monoclonal anti-RAGE antibody (Clone XT-M4) (ABIN7675810) specifically detects RAGE in ELISA, FACS, SPR, BLI and Func.
The antibody is reactive with Human samples.
Catalog No. ABIN7675810
$294.23
$346.15
save $51.92 (-15 %)
Plus shipping costs $50.00
1 mg ABIN7581236
100 μg ABIN7675810
1 mg ABIN7581236
100 μg ABIN7675810
Delivery in 10 to 11 Business Days
Quick Overview for Recombinant RAGE antibody (ABIN7675810)
Target
See all RAGE (AGER) Antibodies
RAGE (AGER)
(Advanced Glycosylation End Product-Specific Receptor (AGER))
Antibody Type
Recombinant Antibody
Reactivity
All reactivities for RAGE antibodies
Human
Host
All hosts for RAGE antibodies
Human
Clonality
All clonalities for RAGE antibodies
Monoclonal
Conjugate
All conjugates for RAGE antibodies
This RAGE antibody is un-conjugated
Application
All applications for RAGE antibodies
ELISA, Flow Cytometry (FACS), Surface Plasmon Resonance (SPR), Bio-Layer Interferometry (BLI), Functional Studies (Func)
Clone
XT-M4
Product Details anti-RAGE Antibody
(hide)
Expression System
CHO Cells
Purpose
Anti-AGER / RAGE Reference Antibody (XT-M4)
Characteristics
Anti-AGER / RAGE Reference Antibody (XT-M4) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
Purity
>95 %
Isotype
IgG1
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Lyophilized
Concentration
1 mg/mL
Buffer
25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
Storage
4 °C,-80 °C
Storage Comment
+4°C,-80°C
Target Details for RAGE
(hide)
Target
RAGE (AGER)
(Advanced Glycosylation End Product-Specific Receptor (AGER))
Alternative Name
AGER
Molecular Weight
145.5 kDa
UniProt
Q15109
Pathways
Carbohydrate Homeostasis , Toll-Like Receptors Cascades , Smooth Muscle Cell Migration , S100 Proteins
Recently viewed
(hide)
Chat with us , powered by LiveChat